Researchers find changes in blood proteins up to two years before breast cancer diagnosis

Barcelona, Spain: Researchers have found changes in the levels of particular proteins in people’s blood up to two years before they were diagnosed with breast cancer. The study, presented at the 13th European Breast Cancer Conference, could form the basis of blood testing for people with a genetic predisposition or a family history of breast […]

Gradual increase in daily activity with psychological therapies can improve mental health for cancer patients and survivors

Barcelona, Spain: Cancer patients and survivors have better mental and physical health and quality of life if they take part in a physical activity programme called ‘behavioural graded activity’ in combination with psychological therapies, according to new research presented at the 13th European Breast Cancer Conference in Barcelona, Spain. Behavioural graded activity involves physiotherapists helping […]

Personalised breast cancer screening could improve cancer survival and reduce overdiagnosis

Barcelona, Spain: Researchers have created a model for predicting individual breast cancer risk that could be used to create personalised breast screening strategies. The research, presented at the 13th European Breast Cancer Conference, could make breast screening programmes more effective and ultimately improve survival rates. It could also mean fewer people experiencing ‘false positives’ – […]

More cancers are diagnosed at an advanced stage if patients already have type 2 diabetes

Barcelona, Spain: A study of 11,945 people in six European countries has shown that people with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if the condition is one that is not screened for routinely. In a presentation to the 13th European Breast Cancer Conference, Dr Anna Jansana, […]

Adversity in childhood is linked to increased risk of heart and blood vessel diseases in early adulthood

Children who experience adversity, including serious family illness or death, poverty, neglect, or dysfunctional and stressful family relationships, are at increased risk of developing diseases of the heart or blood vessels in early adulthood. The new research, which is published in the European Heart Journal [1], is the largest study so far to look at […]

Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer: first results from ARROS-1 phase I clinical trial

Barcelona, Spain: Preliminary data from a phase I clinical trial of a new drug called NVL-520 for patients with non-small cell lung cancer (NSCLC) and other solid tumours, suggest that it may have the potential to both halt tumour growth by inhibiting a cancer-causing gene change, and to reach cancer cells in the brain, with […]

Targeted lung cancer drug shows promise in phase I/II clinical trial

Barcelona, Spain: Early trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain type of non-small cell lung cancer (NSCLC). The results of the TRIDENT-1 trial, which were presented at the 34th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, suggest that repotrectinib could be […]

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial

Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently. Presenting results from the phase Ib STAR [1] clinical trial to the 34th EORTC-NCI-AACR [2] Symposium on Molecular Targets […]

Experimental drug to treat liver cancer shows evidence of activity with manageable side effects

Barcelona, Spain: A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anti-cancer activity with manageable side effects in liver cancer patients who have been treated unsuccessfully previously with up to three lines of treatment. Presenting the findings at the 34th EORTC-NCI-AACR [1] Symposium on […]

AKT inhibitor shows signs of effectiveness in a patient trial matching drugs to tumour gene mutations

Barcelona, Spain: In a trial matching new treatments to cancer patients based on the genetic make-up of their tumours, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumours shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In […]